Abstract
Autonomic nervous system plays a pivotal role in controlling ocular functions starting from aperture and focus control to the production of aqueous humour. It also controls the intrinsic functions and blood supply to various ocular tissues through cholinergic and adrenergic receptors. Cholinergic and adrenergic agonists and antagonists are major class of drugs used in diagnostic and therapeutic purposes in ophthalmology. This chapter is an attempt to review the autonomic nervous system innervations to the ocular structures, their role in carrying out physiological functions of eye and drugs acting through this system as diagnostic, palliative and curative strategies in various ophthalmic conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ackerknecht EH. The history of the discovery of the vegetative (autonomic) nervous system. Med Hist. 1974;18(1):1–8.
Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol. 1991;75:519–23.
Alm A, Nilsson SF. Uveoscleral outflow – a review. Exp Eye Res. 2009;88(4):760–8.
Angenent WJ, Koelle GB. A possible enzymatic basis for the differential action of mydriatics on light and dark irides. J Physiol. 1953;119(1):102–17.
Apatachioae I, Chiseliţa D. Alpha-2 adrenergic agonists in the treatment of glaucoma. Oftalmologia. 1999;47(2):35–40.
Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I, Bagheri A, Givrad S, Yazdani S, Reza Mohebbi M. Optimal dosage of cyclopentolate 1% for complete cycloplegia: a randomized clinical trial. Eur J Ophthalmol. 2007;17(3):294–300.
Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121(12):2348–55.
Bagheri A, Givrad S, Yazdani S, Reza Mohebbi M. Optimal dosage of cyclopentolate 1% for complete cycloplegia: a randomized clinical trial. Eur J Ophthalmol. 2007;17(3):294–300.
Ballin N, Becker B, Goldman ML. Systemic effects of epinephrine applied topically to the eye. Invest Ophthalmol. 1966;125–129.
Bartlett JD, Classé JG. Dapiprazole: will it affect the standard of care for pupillary dilation? Optom Clin. 1992;2(4):113–20.
Battershill PE, Sorkin EM. Ocular metipranolol. Drugs. 1988;36(5):601–15.
Becker HI, Walton RC, Diamant JI, Zegans ME. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol. 2004;122(7):1063–6.
Benovic JL. Novel β2-adrenergic receptor signaling pathways. J Allergy Clin Immunol. 2002;110:S229–35.
Bensinger RE, Keates EU, Gofman JD, Novack GO, Duzman E. Levobunolol: a three-month efficacy study in the treatment of glaucoma and ocular hypertension. Arch Ophthalmol. 1985;103:375–8.
Boger WP, Steinert RF, Puliafito CA, Pavan-Langston D. Clinical trial comparing timolol ophthalmic solution to pilocarpine in open-angle glaucoma. Am J Ophthalmol. 1978;86:8–18.
Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci. 1989;12:148–51.
Boozman FW, Carriker R, Foerster R, Allen RC, Novack GO, et al. Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure. Arch Ophthalmol. 1988;106:614–8.
Boudot JP, Cavero I, Fenard S, Lefevre-Borg F, Manoury P, et al. Preliminary studies on SL 75212, a new potent cardioselective β-adrenoceptor antagonist (Proceedings). Br J Pharmacol. 1979;66:445.
Bremner F. Pupil evaluation as a test for autonomic disorders. Clin Auton Res. 2009;19:88–101.
Bremner FD, Smith SE. Pupil findings in a consecutive series of 150 cases of generalized autonomic neuropathy. J Neurol Neurosurg Psychiatry. 2006;77:1163–8.
Brown RH, Stewart RH, Lynch MG, Crandall AS, Mandell AI, Wilensky JT, et al. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. Ophthalmology. 1988;95:378–84.
Buckley MM, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1990;40(1):75–90.
Casini G, Dal Monte M, Fornaciari I, Filippi L, Bagnoli P. The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res. 2014;42:103–29.
Catford GV, Millis E. Clinical experience in the intra-ocular use of acetylcholine. Br J Ophthalmol. 1967;51:183–7.
Cavero I, Lefevre-Borg F. Antihypertensive activity of betaxolol in conscious spontaneously hypertensive rats (Proceedings). Br J Pharmacol. 1983;78:141.
Chen PL, Hsiao CH, Chen JT, Lu DW, Chen WY. Efficacy of apraclonidine 0.5% in the diagnosis of horner syndrome in pediatric patients under low or high illumination. Am J Ophthalmol. 2006;142:469–74.
Cremer SA, Thompson S, Digree KB, et al. Hydroxyamphetamine mydriasis in Horner’s syndrome. Am J Ophthalmol. 1990;110:71–6.
Cullon Jr RD, Schwartz LW. The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy. Ophthalmic Surg. 1993;24:623–6.
Czarnecki JSC, Pilley SFJ, Thompson HS. The analysis of anisocoria. Can J Ophthalmol. 1979;14:297–302.
Danesh-Meyer HV, Savino P, Sergott R. The correlation of phenylephrine 1% and hydroxyamphetamine 1% in Horner’s syndrome. Br J Ophthalmol. 2004;88:592–3.
Digre KB. Principles and techniques of examination of the pupils, accommodation, and lacrimation. In: Miller NR et al. editor. Walsh and Hoyt’s clinical neuro-ophthalmology. 6th ed. Pennsylvania, USA: Lippincott Williams & Wilkins; 2005. p. 715–37.
Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol. 1987;65(5):618–21.
Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. Br J Ophthalmol. 2003;87(12):1463–5.
Feghali JG, Kaufman PL, Radius RL, Mandell AI. A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. Acta Ophthalmol (Copenh). 1988;66(2):180–6.
Filippi L, Dal Monte M, Casini G, Daniotti M, Sereni F, Bagnoli P. Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system. Med Res Rev. 2015;35(3):619–52.
Fredriksson JM, Lindquist JM, Bronnikov GE, Nedergaard J. Norepinephrine Induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoreceptor/cAMP/protein kinase a pathway involving Src but independently of Erk1/2. J Bioll Chem. 2000;275:13802–11.
Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42(1):96–100. German patent 1,117,588.
Gettes BD, Leopold IH. Evaluation of 5 new cycloplegic drugs. Arch Ophthalmol. 1953;49:24–7.
Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988;95(9):1217–20.
Goldberg I. Betaxolol. Aust N Z J Ophthalmol. 1989;17:9–13.
Gupta N, Drance SM, McAllister R, Prasad S, Rootman J, Cynader MS. Localisation of M3 muscarinic receptor subtype and mRNA in the human eye. Ophthalmic Res. 1994a;26:207–13.
Gupta N, McAllister R, Drance SM, Rootman J, Cynader MS. Muscarinic receptor Ml and M2 subtypes in the human eye: QNB, pirenzipine, oxotremorine, and AFDX-116 in vitro autoradiography. Br J Ophthalmol. 1994b;78:555–9.
Halpern B. Obituary notice: Henry Hallet dale. Rev Fr Allergol. 1969;9(2):117–9.
Hancox J, Murdoch I, Parmar D. Changes in intraocular pressure following diagnostic mydriasis with cyclopentolate 1%. Eye (Lond). 2002;16(5):562–6.
Harley RD, Mishler JE. Acetylcholine in cataract surgery. Br J Ophthalmol. 1966;50:429–33.
Henness S, Swainston Harrison T, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging. 2007;24(6):509–28.
Hogeling M. Propranolol for infantile hemangiomas: a review. Curr Dermatol Rep. 2012;1(4):179–85.
Holmwood PC, Chase RD, Krupin T, Rosenberg LF, Ruderman JM, Tallman BA, et al. Apraclonidine and argon laser trabeculoplasty. Am J Ophthalmol. 1992;114:19–22.
Hong C, Song KY, Park WH, Sohn YH. Effect of apraclonidine hydrochloride on acute intraocular pressure rise after argon laser iridotomy. Korean J Ophthalmol. 1991;5:37–41.
Hurvitz LM, Kaufman PL, Robin AL, et al. New developments in the drug treatment of glaucoma. Drugs. 1991;41(4):514–32.
Iribarren R. Tropicamide and myopia progression. Ophthalmology. 2008;115(6):1103–4.
Jacobson DM. Pupillary response to dilute pilocarpine in pre-ganglionic 3rd nerve disorders. Neurology. 1990;40:804–8. PubMed.
Jacobson DM, Vierkant RA. Comparison of cholinergic supersensitivity in third nerve palsy and Adie’s syndrome. J Neuro Ophthalmol. 1998;18:171–5.
Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005;89(6):758–63.
Kardon R. Anatomy and physiology of the autonomic nervous system. In: Miller NR et al. editor. Walsh and Hoyt’s clinical neuro-ophthalmology. 6th ed. Pennsylvania, USA: Lippincott Williams & Wilkins; 2005. p. 649–714.
Kardon RH, Denison CE, Brown CK, et al. Critical evaluation of the cocaine test in the diagnosis of Horner’s syndrome. Arch Ophthalmol. 1990;108:384–7.
Kardon RH, Corbett JJ, Thompson HS. Segmental denervation and reinnervation of the iris sphincter as shown by infrared videographic transillumination. Ophthalmology. 1998;105:313–21.
Kaufman PL. Mechanisms of actions of the cholinergic drugs in the eye. In: Drance SM, Neufeld AN, editors. Glaucoma. 1st ed. Orlando: Grune and Stratton; 1984. p. 295–327.
Kawasaki A. Disorders of pupillary function, accommodation, and lacrimation. In: Miller NR et al. editor. Walsh and Hoyt’s clinical neuro-ophthalmology. 6th ed. Pennsylvania, USA: Lippincott Williams & Wilkins; 2005. p. 739–805.
Khurana AK, Ahluwalia BK, Rajan C. Status of cyclopentolate as a cycloplegic in children: a comparison with atropine and homatropine. Acta Ophthalmol (Copenh). 1988;66(6):721–4.
Krieglstein GK, Novack GO, Voepel E, Schwarzbach G, Lange U, et al. Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort. Br J Ophthalmol. 1987;71:250–3.
Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature. 1986;323:411–6.
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.
Lowenstein O, Loewenfeld IE. Mutual role of sympathetic and parasympathetic in shaping of the pupillary reflex to light: pupillographic studies. Arch Neurol Psychiatry. 1950;64:341–77.
Maren N, Alvan G, Calissendorff BM, et al. Additive intraocular pressure reducing effect of topical timolol during systemic beta- blockade. Acta Ophthalmol. 1982;60:16–23.
Marron J. Cycloplegia and mydriasis by use of atropine, scopolamine and homatropine-paredrine. Arch Ophthalmol. 1940;23:340–50.
McDougal DH, Gamlin PD. Autonomic control of the eye. Compr Physiol. 2015;5(1):439–73.
Melles RB, Wong IG. Metipranolol-associated granulomatous iritis. Am J Ophthalmol. 1994;118(6):712–5.
Merrill DL, Goldberg B, Zavell S. bis tropicamide. A new parasympatholytic. Curr Ther Res. 1960;2:43–50.
Merte HI, Schnarr KD. Ophthalmic betaxolol: a twelve-week study in glaucoma patients. New Trends Ophthalmol. 1987;2:98–108.
Merte H-J, Stryz JR, Mertz M. Comparative studies of initial pressure reduction using metipranolol 0.3% and timolol 0.25% in eyes with open-angle glaucoma. Klin Monbl Augenheilkd. 1983;182:286–9.
Milder B. Tropicamide as a cycloplegic agent. Arch Opthalmol. 1961;66:70–2.
Mills KB, Wright G. A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study. Br J Ophthalmol. 1986;70:39–42.
Mindel JS. Cholinergic pharmacology, chap 26. In: Duane TD, Jaeger EA, editors. Biomedical foundations of ophthalmology, vol. 3. Philadelphia: Harpel & Row; 1982.
Mircheff AK. Lacrimal fluid and electrolyte secretion: a review. Curr Eye Res. 1989;8(6):607–17.
Mirza GE, Karakuçuk S, Temel E. Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. J Glaucoma. 2001;9(1):45–50.
Montanari P, Marangoni P, Oldani A, Ratiglia R, Raiteri M, Berardinelli L. Color Doppler imaging study in patients with primary open-angle glaucoma treated with timolol 0.5% and carteolol 2%. Eur J Ophthalmol. 2001;11(3):240–4.
Mori A, Miwa T, Sakamoto K, Nakahara T, Ishii K. Pharmacological evidence for the presence of functional beta(3)-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(2):119–26.
Morrison JC, Robin AL. Adjunctive glaucoma therapy: a comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology. 1989;96(1):3–7.
Moss AP, Ritch R, Hargett NA, et al. A comparison of the effects of timolol and epinephrine on intraocular pressure. Am J Ophthalmol. 1978;86:489–95.
Mundasad MV, Novack GD, Allgood VE, Evans RM, Gorden JC, Yerxa BR. Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. J Ocul Pharmacol Ther. 2001;17(2):173–9.
Murakami T, Fujihara T, Nakamura M, Nakata K. P2Y(2) receptor stimulation increases tear fluid secretion in rabbits. Curr Eye Res. 2000;21(4):782–7.
Neufeld AH, Bartels SP, Liu JHK. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol. 1983;28(1):286–90.
Neuhuber W, Schrödl F. Autonomic control of the eye and the iris. Auton Neurosci. 2011;165(1):67–79.
Nielsen CB, Nielsen PJ. Effect of alpha- and beta-receptor active drugs on corneal thickness. Acta Ophthalmol (Copenh). 1985;63(3):351–4.
Obianwu HO, Rand MJ. The relationship between the mydriatic action of ephedrine and the colour of the iris. Br J Ophthalmol. 1965;49:264.
Park SY, Kang JH, Jeong KJ, Lee J, Han JW, Choi WS, Kim YK, Kang J, Park CG, Lee HY. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism. Int J Cancer. 2011;128:2306–16.
Pilley S, Thompson HS. Pupillary ‘dilatation lag’ in Horner’s syndrome. Br J Ophthalmol. 1975;59:731–5.
Pollack IP, Brown RH, Crandall AS, Robin AL, Stewart RH, White GL. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. Arch Ophthalmol. 1988;106:754–7.
Priestly BS, Medine MM. A new mydriatic and cycloplegic drugs. Am J Opthalmol. 1951;34:572–5.
Rakofsky SI, Lazar M, Almog Y, LeBlanc RP, Mann C, Orr A, Lee PF, Friedland BR, Novack GD, Kelley EP. Efficacy and safety of once-daily levobunolol for glaucoma therapy. Can J Ophthalmol. 1989;24(1):2–6.
Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology. 1983;90:1369–72.
Rengstorff RH, Doughty CB. Mydriatic and cycloplegic drugs: a review of ocular and systemic complications. Am J Optom Physiol Opt. 1982;59(2):162–77. Review.
Robin AL, Pollack IP, deFaller JM. Effects of ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. Arch Ophthalmol. 1987a;105:1208–11.
Robin AL, Pollack IP, House B, Enger C. Effects of ALO2145 on IOP following argon laser trabeculoplasty. Arch Ophthalmol. 1987b;105:646–50.
Rolle BB, Franzone M. Effects of topical betaxolol on ocular hypertensive or glaucomatous eyes. New Trends Ophthalmol. 1987;2:87–94.
Rosenberg LF, Krupin T, Ruderman J, McDaniel DL, Siegfried C, Karalekas DP, Grewal RK, Gieser DK, Williams R. Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% Apraclonidine for prevention of postoperative intraocular pressure rise. Ophthalmology. 1995;102(9):1312–8.
Sanderson J, Dartt DA, Trinkaus-Randall V, et al. Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Müller cells, lens, trabecular meshwork, cornea and lacrimal gland. Exp Eye Res. 2014;127:270–9.
Schmitz-Valckenberg P, Jonas J, Brambring DF. Reductions in pressure with metipranolol 0.1 %. Zeitschrift fur Praktische Augenheilkunde. 1984;5:171–5.
Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol. 1988;105(2):150–4.
Selvam S, Mircheff AK, Yiu SC. Diverse mediators modulate the chloride ion fluxes that drive lacrimal fluid production. Invest Ophthalmol Vis Sci. 2013;54(4):2927–33.
Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2013;2, CD006539.
Shutt LE, Bowes JB. Atropine and hyoscine. Anesthesia. 1979;34:476–90.
Siderov J, Nurse S. The mydriatic effect of multiple doses of tropicamide. Optom Vis Sci. 2005;82(11):955–8.
Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, et al. Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure. Am J Ophthalmol. 1991;112:56–60.
Smit DP. Pharmacological testing in Horner’s syndrome – a new paradigm. S Afr Med J. 2010;100:738–40.
Smith SA, Smith SE. Bilateral Horner’s syndrome: detection and occurrence. J Neurol Neurosurg Psychiatry. 1999;66:48–51.
Smith JP, Weeks RH, Newland EF, Ward RL. Betaxolol and acetazolamide: combined ocular hypotensive effect. Arch Ophthalmol. 1984;102:1794–5.
Sneader W. The discovery and synthesis of epinephrine. Drug News Perspect. 2001;14(8):491–4.
Sonty S, Schwartz B. The additive effect of timolol on open angle glaucoma patients on maximal medical therapy. Surv Ophthalmol. 1979;23:381–8.
Spehlmann R. Acetylcholine facilitation, atropine block of synaptic excitation of cortical neurons. Science. 1969;165(3891):404–5.
Steward WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Hoskins HD, Hetherington JN, Bahr RL, Noblin JE, Delehanty JT. A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1991;229(3):258–61.
Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader C, van Buskirk EM. The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol. 1995;113:287–92.
Stryz JR, Merte H-J. Comparison of different i3-blockers in open angle glaucomas. In: Greve EL et al., editors. Second european glaucoma symposium, Helsinki, 1984. Dordrecht: Dr W. Junk Publishers; 1985. p. 119–23.
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939–44.
Toda N, Toda M, Ayajiki K, Okamura T. Monkey central retinal artery is innervated by nitroxidergic vasodilator nerves. Invest Ophthalmol Vis Sci. 1996;37(11):2177–84.
Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995a;113(12):1514–7.
Toris CB, Tafoya ME, Camras CB, Yabloniski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995b;102:456–61.
Vidal-Sanz M, Lafuente MP, Mayor S, de Imperial JM, Villegas-Pérez MP. Retinal ganglion cell death induced by retinal ischemia. neuroprotective effects of two alpha-2 agonists. Surv Ophthalmol. 2001;45 Suppl 3:S261–7; discussion S273–6.
Vogt M. Obituary. Sir Henry Hallett Dale, O.M., F.R.S. Int J Neuropharmacol. 1969;8(2):83–4.
Wachler BSB, Krueger RR. Agreement and repeatability of infrared pupillometry and the comparison method. Ophthalmology. 1999;106:319–23.
Wandel T, Charap AD, Lewis RA, Partamian L, Cobb S, et al. Glaucoma treated with once-daily levobunolol. Am J Ophthalmol. 1986;101:298–304.
Wilhelm H, Wilhelm B. Clinical applications of pupillography. J Neuro Ophthalmol. 2003;23:42–9.
Wood JP, Schmidt KG, Melena J, Chidlow G, Allmeier H, Osborne NN. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp Eye Res. 2003;76(4):505–16.
Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009;18(5):395-8.
Yüksel N, Güler C, Çaglar Y, Elibol O. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. International Ophthalmology. 1992;16(4):337–42.
Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95(4):601–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Halder, N., Saxena, R., Phuljhele, S., Velpandian, T. (2016). Drugs Acting Through Autonomic System for Ocular Use. In: Velpandian, T. (eds) Pharmacology of Ocular Therapeutics. Adis, Cham. https://doi.org/10.1007/978-3-319-25498-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-25498-2_6
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-25496-8
Online ISBN: 978-3-319-25498-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)